Recent Quotes (30 days)

You have no recent quotes
chg | %

Helix Biopharma Corp.  

(Public, TSE:HBP)   Watch this stock  
Find more results for HBP
1.55
0.00 (0.00%)
Dec 2 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 1.40 - 2.25
Open     -
Vol / Avg. 0.00/1,761.00
Mkt cap 139.51M
P/E     -
Div/yield     -
EPS -0.11
Shares 90.01M
Beta -0.22
Inst. own 0%
Dec 9, 2016
Q1 2017 Helix Biopharma Corp Earnings Release (Estimated) Add to calendar
Oct 31, 2016
Q4 2016 Helix Biopharma Corp Earnings Release
  

Key stats and ratios

Q3 (Jul '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -207.83% -157.62%
Return on average equity -286.11% -193.47%
Employees 15 -
CDP Score - -

Address

3-305 Industrial Pky S
AURORA, ON L4G 6X7
Canada
+1-905-8412300 (Phone)
+1-905-8412244 (Fax)

Website links

Description

Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).

Officers and directors

Sven Rohmann M.D., Ph.D. Chairman of the Board, Chief Executive Officer
Age: 52
Photios Michalargias Chief Financial Officer
Age: 50
Patrick Frankham Ph.D. Chief Operating Officer
Age: 43
Heman Chao Ph.D. Chief Scientific Officer
Age: 51
George J. Anders Director
Albert G. Beraldo Director
Sylwester Eugeniusz Cacek Director
Theordore Witek Jr. Director
Slawomir Majewski M.D. Independent Director
Age: 57